This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CCP110 / Centriolar coiled-coil protein of 110 kDa · IHC design guide
Design Immunohistochemistry for CCP110
For paraffin-section CCP110 IHC, use catalog antibody A05058-1 with chromogenic detection (datasheet A05058-1). Compare high-staining bronchial ciliated cells and late spermatids with adipocytes, where staining was not detected, and interpret granular cytoplasmic staining in light of low antibody–RNA consistency (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CCP110 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Granular cytoplasm (HPA tissue IHC); centrioles (UniProt) | |
| Staining pattern | Granular cytoplasm in most tissues, including testis (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A05058-1) | |
| Positive control | Bronchus+4 more · see all | |
| Negative control | Adipose tissue+1 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Antibody staining shows low consistency with RNA (HPA tissue IHC) | |
| Regulation | NEURL4 and CCNF promote degradation (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope differences unspecified (UniProt) |
Section 1
Recommended CCP110 IHC & IF Protocols
The catalog antibody protocol uses EDTA retrieval (datasheet A05058-1); the published tissue-section protocol uses citrate retrieval (PMC9996364).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A05058-1) |
| Fixation | Image fixative and duration unreported (datasheet A05058-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A05058-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A05058-1) |
| Primary antibody | Rabbit anti-CCP110, 2-5μg/ml (datasheet A05058-1) |
| Primary incubation | Overnight at 4 °C (datasheet A05058-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A05058-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CCP110-positive staining in ciliated cells (cell body) of bronchus (HPA tissue IHC: High). HPA tissue profile: Granular cytoplasmic expression in most tissues, including testis. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval for the catalog antibody (datasheet A05058-1). Citrate pH 6.0 is the published alternative for a different CCP110 antibody (PMC9996364).
Section 2
What Is the Expected CCP110 Staining Pattern?
CCP110 localizes to centrioles and basal bodies (UniProt O43303) and to centriolar satellites in ICC-IF (HPA: approved subcellular location). In tissue IHC, expect granular cytoplasmic staining, especially in bronchial ciliated cell bodies and late spermatids (HPA: High in both). HPA rates its tissue IHC staining Approved but reports low consistency with RNA expression (HPA: tissue IHC reliability). CCP110 has no transmembrane segment (UniProt O43303 topology).
| Granular cytoplasmic stain in bronchial ciliated cell bodies or testicular late spermatids. | This matches HPA's observed pattern and High staining in those cells (HPA: tissue IHC). Score the named cell population and compartment; adjacent cells need not share its intensity (general IHC practice). |
| Predominantly nuclear, sharply membranous, or extracellular deposit. | These compartments do not match CCP110's annotated centrosome, centriole, and basal-body locations (UniProt O43303) or HPA's granular cytoplasmic tissue pattern (HPA: tissue IHC). Check morphology and controls before calling the deposit specific (general IHC practice). |
| Strong stain in adipocytes or smooth muscle cells, especially without the expected positive-cell pattern. | HPA reports CCP110 as not detected in these cells (HPA: adipose tissue; smooth muscle). Investigate cross-reactivity, endogenous detection activity, or nonspecific chromogen deposition with appropriate controls (general IHC practice). |
| Haze or precipitate extends across many cell types and obscures granules. | That distribution cannot establish the reported granular cytoplasmic pattern (HPA: tissue IHC). Review reagent-only controls, blocking, washes, and chromogen development; background has several possible causes (general IHC practice). |
| No convincing stain in bronchial ciliated cells or testicular late spermatids. | Both are reported High by HPA tissue IHC, so an absent signal warrants a run-level check (HPA: bronchus; testis). Confirm tissue preservation and cell identity, then review the antibody's validated IHC-P conditions and positive control (general IHC practice). |
💡Expected CCP110 appearanceCall a positive result when granular cytoplasmic staining is clear in bronchial ciliated cell bodies or late spermatids, where HPA reports High signal; isolated nuclear, membranous, or extracellular color is inconsistent with the annotated localization (HPA: tissue IHC; UniProt O43303).
| Cell type and tissue choice | Bronchial ciliated cells and late spermatids provide reported High staining; several glandular, hematopoietic, Purkinje, and glial populations are Medium, while adipocytes and smooth muscle cells are not detected (HPA: tissue IHC). |
| Resolution and cellular state | UniProt places CCP110 at centrioles and basal bodies and describes removal from the mother centriole during ciliogenesis (UniProt O43303). HPA's tissue result is granular cytoplasmic; do not require every chromogenic granule to resolve as an individual centriole (HPA: tissue IHC; general light-microscopy practice). |
| Strength of validation | The listed antibody HPA039402 is IHC Approved, while HPA reports low consistency between tissue staining and RNA expression (HPA: antibody validation; tissue IHC reliability). Treat unexpected cell-type staining as a finding to verify, not an established CCP110 distribution. |
| Isoforms and epitope | UniProt lists 2 isoforms but supplies no antibody epitope or isoform-specific staining result here (UniProt O43303). Check the antibody documentation before assigning differences in tissue staining to an isoform (general IHC practice). |
| IF/ICC Q&A | Where should IF/ICC signal appear? HPA reports an approved centriolar-satellite location in ICC-IF images from REH, U-251MG, and sperm (HPA: subcellular ICC-IF). This supports an IF localization check; it does not set an IHC-P protocol or guarantee the same apparent pattern in sections. |
| Situation | Likely cause | Next action |
|---|---|---|
| High background throughout the section | Nonspecific binding, insufficient washing, or detection activity may obscure the reported granular cytoplasmic pattern (general IHC practice; HPA: tissue IHC). | Compare a reagent-only or primary-omission control; review blocking, washes, and chromogen development, then reassess whether cell-associated granules remain (general IHC practice). |
| Signal appears nuclear or outlines cell membranes | The distribution conflicts with the reported cytoskeletal centrosome/centriole localization and absence of a transmembrane segment (UniProt O43303). | Check tissue morphology and control sections; interpret this signal cautiously unless the expected granular cytoplasmic pattern is also supported (HPA: tissue IHC; general IHC practice). |
| Adipocytes or smooth muscle cells stain strongly | These populations are reported as not detected (HPA: tissue IHC); cross-reactivity or endogenous detection activity is possible (general IHC practice). | Compare a primary-omission control and a known-positive cell population on the same run before assigning specificity (general IHC practice; HPA: bronchus; testis). |
| No signal in the expected positive cells | The assay may have failed, the relevant cells may be absent from the section, or the run conditions may be unsuitable (general IHC practice). | Locate bronchial ciliated cells or late spermatids, both reported High, and verify the antibody's IHC-P conditions and control performance (HPA: tissue IHC; general IHC practice). |
| Weak stain is seen only in a mixed-cell tissue | HPA records Medium staining in several selected populations; whole-section impressions can hide cell-specific signal (HPA: tissue IHC; general IHC practice). | Score the named population and its granular cytoplasmic distribution, then compare with a bronchus or testis positive reference if available (HPA: tissue IHC; general IHC practice). |
| IHC granules do not resemble discrete ICC-IF puncta | HPA describes granular cytoplasmic tissue IHC and centriolar satellites in ICC-IF; the two observations use different preparations and readouts (HPA: tissue IHC; subcellular ICC-IF). | Judge the paraffin-section result against the reported IHC cell types and compartment. Use the separate IF/ICC guide for fluorescence localization work (HPA: tissue IHC; subcellular ICC-IF). |
Experiment evidence
IHC & IF images showing CCP110 staining
A05058-1 · IHCIHC analysis of CP110 using anti-CP110 antibody (A05058-1). CP110 was detected in a paraffin-embedded section of human breast cancer tissue.
A05058-1 · IHCIHC analysis of CP110 using anti-CP110 antibody (A05058-1). CP110 was detected in a paraffin-embedded section of human colorectal adenocarci
A05058-1 · IFIF analysis of CP110 using anti-CP110 antibody (A05058-1). CP110 was detected in an immunocytochemical section of HELA cells. Enzyme antigen
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000103540-CCP110/tissue/cerebral+cortex#imid_10232197
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000103540-CCP110/tissue/colon#imid_10232123
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000103540-CCP110/tissue/liver#imid_10232132
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000103540-CCP110/tissue/kidney#imid_10232125
HPA · ICC-IF REHHuman Protein Atlas immunofluorescence, REH, antibody HPA039402; green = CCP110, blue = nucleus, red = microtubules.
HPA · ICC-IF REHHuman Protein Atlas immunofluorescence, REH, antibody HPA039402; green = CCP110, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CCP110 IHC & IF
🧪Run bronchus first and require staining in ciliated-cell bodies (HPA: High in bronchial ciliated cells); use adipose tissue adipocytes as the negative tissue (HPA: Not detected in adipocytes). On the bronchus slide, identify internal negative cells by their absence of the ciliated-cell staining pattern, and verify that absence on the slide rather than assuming every neighboring cell is negative (HPA: High in ciliated-cell bodies; standard IHC practice).
Positive control tissue: Bronchus (Ciliated cells (cell body), HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show CCP110 in REH, U-251MG, Sperm, with annotated localisation: Centriolar satellite (approved) (HPA subcellular).
Technical controls: Run no-primary (secondary-only) and rabbit IgG isotype controls matched to the primary antibody’s format, plus CCP110 knockout material if available (caption: rabbit primary; standard IHC practice). Quench endogenous peroxidase for HRP/DAB detection and check bronchial mucus for background; for IF, assess autofluorescence with a no-primary control (caption: HRP/DAB; standard IHC/IF practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A05058-1 paraffin-section caption does not state the fixative (caption: paraffin section; fixative unreported). Its IHC example uses heat retrieval in EDTA at pH 8.0 and 2 μg/ml primary antibody overnight at 4°C, providing a starting condition to optimize on bronchus (caption: retrieval and primary incubation; HPA: High in bronchial ciliated cells). Frozen-section performance is unreported; IF/ICC may make centriolar-satellite puncta easier to resolve, while bronchial cilia and luminal mucus can complicate chromogenic signal scoring (HPA: centriolar-satellite ICC-IF; HPA: bronchial ciliated cells; standard IHC/IF practice).
HPA tissue IHC evidence for CCP110
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bronchus | Ciliated cells (cell body) | High | Protein (IHC) | HPA → |
| Testis | Elongated or late spermatids | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Medium | Protein (IHC) | HPA → |
Section 3
Advanced CCP110 IHC Tips
Troubleshoot CCP110 staining in paraffin sections by checking retrieval, staining pattern and controls before comparing samples (datasheet A05058-1; UniProt O43303 localisation; standard IHC practice).
Which retrieval conditions should I try first for CCP110 IHC?
Start with heat-mediated antigen retrieval in EDTA pH 8.0 for paraffin sections (datasheet A05058-1). The illustrated section used this retrieval before 10% goat-serum blocking and 2 μg/ml primary incubation overnight at 4°C (datasheet A05058-1). If staining is weak, compare 10 and 20 minutes of heating on adjacent sections while keeping cooling, detection and antibody concentration identical (standard IHC practice). Score focal and diffuse staining separately, because CCP110 associates with centrioles while HPA describes granular cytoplasmic expression; also inspect morphology for heat damage (UniProt O43303 localisation; HPA tissue IHC; standard IHC practice).
How should I handle uncertain fixation effects on CCP110 staining?
Target-specific fixation sensitivity is unknown, and the selected paraffin-section caption does not state its fixative (datasheet A05058-1). Record the actual fixative, fixation interval, block age and section thickness before comparing staining across specimens (standard IHC practice). If fixation varies, compare matched material using EDTA pH 8.0 retrieval and the illustrated 2 μg/ml primary concentration, assessing morphology and signal together (datasheet A05058-1; standard IHC practice). Do not assign weak staining to CCP110 phosphosites or its lack of a transmembrane segment without a controlled fixation comparison (UniProt O43303 modifications and topology; standard IHC practice).
Where should CCP110 staining appear in tissue sections?
Look for focal cytoplasmic staining consistent with centrioles or basal bodies, where CCP110 localizes (UniProt O43303 localisation). In routine chromogenic sections, these structures may be difficult to resolve individually; HPA instead describes granular cytoplasmic expression across most tissues (HPA tissue IHC; standard IHC practice). HPA reports high staining in bronchial ciliated-cell bodies and elongated or late testicular spermatids, providing cell-level comparators (HPA tissue IHC). Compare adjacent sections within the same cell population, and reassess a nuclear-only pattern before calling it CCP110 (UniProt O43303 localisation; standard IHC practice).
Can this antibody distinguish CCP110 isoforms or phosphorylation states in IHC?
CCP110 has 2 annotated isoforms and multiple phosphosites, but the supplied caption gives no epitope map or isoform-specific validation for this antibody (UniProt O43303 isoforms and modifications; datasheet A05058-1). Treat staining as antibody-reactive CCP110 until immunogen coverage across both isoforms is established (standard IHC practice). Compare sections processed with identical EDTA pH 8.0 retrieval and 2 μg/ml primary concentration so processing differences do not imitate epitope loss (datasheet A05058-1; standard IHC practice). An intensity change alone cannot identify phosphorylation at Ser170 or Thr194; that requires site-specific validation or an orthogonal assay (UniProt O43303 modifications; standard IHC practice).
How can IF clarify an ambiguous chromogenic CCP110 pattern?
Use IF on matched material to examine whether IHC granules correspond to centriole-associated CCP110 (UniProt O43303 localisation; standard IF practice). Include a validated marker of the expected cell type; for bronchus, a ciliated-cell marker helps identify the population whose cell bodies stain strongly in HPA IHC (HPA tissue IHC; standard IF practice). Select separated fluorophores, place a weak CCP110 signal in a channel with low tissue autofluorescence, and run single-label controls (standard IF practice). Because CCP110 is intracellular and has no transmembrane segment, use controlled permeabilisation to reach its cytoplasmic or centriolar epitope, then compare the IF pattern with IHC (UniProt O43303 topology and localisation; standard IF practice).
How can I reduce diffuse brown staining without losing CCP110 signal?
Compare a no-primary control with the test section to distinguish antibody-independent deposits from primary-dependent staining (standard IHC practice). Block endogenous peroxidase before HRP detection and check whether DAB product persists without primary antibody; the selected image used HRP and DAB (datasheet A05058-1; standard IHC practice). Use the illustrated 10% goat-serum block and 2 μg/ml primary as reference conditions, then titrate primary concentration or DAB development on adjacent sections (datasheet A05058-1; standard IHC practice). Preserve interpretable granular cytoplasmic staining while treating widespread haze that ignores cell boundaries as suspect (HPA tissue IHC; standard IHC practice).
How should I quantify CCP110 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the eligible cell population and cytoplasmic compartment before scoring, since HPA describes granular cytoplasm and CCP110 associates with centrioles and basal bodies (HPA tissue IHC; UniProt O43303 localisation). Report an H-score on a 0–300 scale from percentages of cells at 0–3 intensity, together with percent positive cells (standard IHC practice). If individual foci are resolvable, report their density per mm² and normalize it to evaluable target cells or tissue area (standard IHC practice). Hold section thickness, retrieval, DAB timing and imaging settings constant; exclude folds and necrosis using a documented threshold and negative controls (standard IHC practice).
When is CCP110 staining convincing rather than artefactual?
A plausible result combines cytoplasmic granules or focal centriolar staining with an expected population, such as bronchial ciliated cells or late testicular spermatids (HPA tissue IHC; UniProt O43303 localisation). Reassess nuclear-only staining, tissue-edge enhancement and necrotic deposits against morphology and the expected compartment (UniProt O43303 localisation; standard IHC practice). Check no-primary and endogenous-peroxidase controls for brown deposits, and compare the pattern with relevant positive and negative cell populations (HPA tissue IHC; standard IHC practice). HPA marks its tissue staining approved but reports low consistency with RNA expression, so confirm surprising patterns with an independent antibody or orthogonal readout (HPA tissue IHC; standard IHC practice).
Boster reagents
Best CCP110 / Centriolar coiled-coil protein of 110 kDa IHC Antibodies
Anti-CCP110 A05058-1 shows IHC in human paraffin tumor sections and IF in HELA cells (catalog image captions); listed reactivity covers human, mouse and rat (catalog reactivity).
Real IHC data
Anti-CP110/CCP110 Antibody ®
Cat # A05058-1
A05058-1 has IHC images from human paraffin sections of breast cancer, colorectal adenocarcinoma and testicular germ cell tumor (catalog IHC captions). A05058-1 also has an IF image from HELA cells (catalog IF caption).
Which to pick: For tissue IHC, choose A05058-1 based on its human paraffin-section images; the fixative is unreported (catalog IHC captions). For IF/ICC, the same SKU lists both applications and shows IF in HELA cells (catalog applications; catalog IF caption). For mouse or rat samples, A05058-1 lists reactivity with both species, but its supplied images show human samples; the antibody is rabbit-hosted and its clonality is unreported (catalog reactivity, image captions, host and clone fields).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O43303 (CP110_HUMAN, Centriolar coiled-coil protein of 110 kDa).
- Human Protein Atlas. CCP110 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. CCP110 subcellular location (ICC-IF): Localized to the centriolar satellites..
- Human Protein Atlas. CCP110 antibody validation summary (1 antibodies).
- lncRNA XIST/miR‑129‑2‑3p axis targets CCP110 to regulate the proliferation, invasion and migration of endometrial cancer cells. Experimental and therapeutic medicine 2023 — PMC9996364.
- Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs. Cancer research 2018 — PMC6139068.
- CEP76 impairment at the centrosome-cilium interface contributes to a spectrum of ciliopathies. Science advances 2025 — PMC12533646.
- PubMed PMID:9455477 — UniProt-cited evidence.
- PubMed PMID:17974005 — UniProt-cited evidence.
- PubMed PMID:10493829 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CCP110 (Centriolar coiled-coil protein of 110 kDa). Expected localisation Granular cytoplasm (HPA tissue IHC); centrioles (UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A05058-1). Validated IHC antibody: A05058-1 at 2-5μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Bronchus (Ciliated cells (cell body)); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A05058-1); 2. Fixation: Image fixative and duration unreported (datasheet A05058-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A05058-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A05058-1); 8. Primary antibody: Rabbit anti-CCP110, 2-5μg/ml (datasheet A05058-1); 9. Primary incubation: Overnight at 4 °C (datasheet A05058-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Antibody staining shows low consistency with RNA (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope differences unspecified (UniProt); Regulation: NEURL4 and CCNF promote degradation (UniProt). Evidence: UniProt O43303, HPA tissue IHC · Approved, HPA ICC-IF · centriolar satellites., Datasheet A05058-1, PMC9996364. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CCP110/immunohistochemistry-ihc-guide.